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intrOdUctiOn
Emergency physicians must be comfortable and 
confident in providing safe and effective procedural sedation 
and analgesia (PSA). Goals of PSA include providing an 
adequate level of sedation while minimizing pain and anxiety, 
maximizing amnesia, minimizing the potential for adverse 
drug-related events, controlling behavior, and maintaining 
a stable cardiovascular and respiratory status. The ideal 
pharmacologic agent for PSA would accomplish all of these 
goals, and would have a quick onset and offset, be safe in 
all age groups, be inexpensive, and be equally efficacious 
in multiple routes of administration. Unfortunately, at this 
time no single agent exists that has all of the aforementioned 
qualities, so physicians must use combinations of different 
drugs at varying does to achieve as many of the desired 
goals as possible. The most recent PSA combination to be 
described in the literature is that of low-dose ketamine and 
propofol (“ketofol”). In this article we attempt to describe 
the postulated benefits of using these two agents together and 
examine the safety and efficacy of the combination.
Background
Ketamine was developed in the 1960s as a safer and more 
predictable anesthetic than its precursor phencyclidine (PCP). 
It is a unique agent in procedural sedation and analgesia 
(PSA) in that it is a “dissociative” anesthetic that functions 
by blocking communication between the thalamic and limbic 
regions of the brain, thereby preventing the brain from 
processing external stimuli.1 It provides excellent amnesia and 
analgesia, and preserves muscle tone maintaining protective 
airway reflexes and spontaneous respiration.2,3 Despite its 
obvious advantages over other agents, some practitioners are 
hesitant to use ketamine alone secondary to its propensity to 
cause vivid and frightening emergenct reactions.4 Additional 
significant adverse effects include sympathomimetic effects 
and vomiting when administered in sedating doses.5
Propofol is a non-barbiturate sedative hypnotic 
developed in Europe in the 1970s and was gradually utilized 
by anesthesiologists in the United States over the next two 
decades. Relatively recently its use has spread into the 
Emergency Department (ED) as a part of PSA. Its popularity 
as a PSA agent is growing rapidly due mainly to its favorable 
pharmacokinetic profile as the lipid solubility confers a quick 
onset and short recovery time.6 It also has the advantages 
of functioning as an antiemetic, an anticonvulsant, and an 
amnestic agent.7 Although extremely effective and potent, 
propofol use is limited by a relatively high incidence of dose-
dependant hypotension and respiratory depression.7,8,9
It is postulated that combining these two agents for 
PSA may preserve sedation efficacy while minimizing 
their respective adverse effects. This is due partly to the 
fact that many of the aforementioned potential adverse 
effects are dose-dependant, and when used in combination 
the doses administered of each can be reduced.10 Also, the 
cardiovascular effects of each are opposing in action, thus 
theoretically balancing each other out when used together. 
This theoretical advantage of ketofol producing a more 
stable hemodynamic and respiratory profile was tested and 
found to be true in a group of healthy patients receiving 
general anesthesia.11 Although there is a significant amount 
of literature describing the use of ketofol in infusion form, in 
this article we attempt to review all the published literature 
describing the use of ketofol in bolus form as would be 
applicable for PSA in the ED.
MethOds
Both MEDLINE and Pubmed were searched using 
ketamine, propofol, ketofol, conscious sedation, and 
procedural sedation as search terms. This resulted in the 
identification of 31 abstracts. All abstracts were reviewed and 
those that described the use of the combination of ketamine 
and propofol in intravenous bolus form were included for 
review. Those that described studies in animals, in healthy 
volunteers, or that described the administration of propofol 
and ketamine either in isolation, in infusion form, or for 
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the references of all included articles was performed using 
the same inclusion and exclusion criteria to ensure that no 
relevant articles were missed. 
literatUre review
Six studies met inclusion criteria and are further discussed 
(Table).
Ketofol versus Propofol
There are two published trials in pediatric patients 
comparing propofol monotherapy to ketofol. The first is a 
randomized double-blind study in 60 patients between one 
month and 13 years of age undergoing cardiac catheterization 
who received sedation with propofol (1.5 mg/kg) monotherapy 
or propofol (1.5 mg/kg) plus ketamine (0.5 mg/kg).12 Mean 
arterial pressure (MAP), heart rate, respiratory rate, and 
peripheral oxygen saturation were recorded at pre-determined 
time intervals. Time to recovery and adverse events were also 
noted. They found a significant (defined a priori as >20%) 
decrease in MAP in 11 patients in the propofol monotherapy 
group and three patients in the ketofol group. No other 
significant differences in recorded vital-sign measurements 
were found. Time to recovery was almost identical in the two 
groups, and the number of adverse events was not statistically 
different. These findings led the authors to conclude that the 
addition of low-dose ketamine to propofol preserved MAP 
without prolonging recovery or increasing the incidence of 
adverse events.
In the second pediatric study propofol (1.5 mg/kg) 
monotherapy was compared to propofol (1.5 mg/kg) plus 
ketamine (0.5 mg/kg) in a non-randomized trial in 60 patients 
between one and 13 years of age undergoing auditory 
brainstem response testing.13 Sedation was maintained with 
repeat boluses at half the original doses at the discretion of 
the treating physician. Blood pressure, respiratory rate, and 
peripheral oxygen saturation were recorded at pre-determined 
time intervals. Desaturation was defined as a 10% decrease in 
peripheral oxygen saturation when compared to baseline, and 
apnea was defined as cessation of respiration for 15 seconds or 
more. The investigators noted that a repeat dose of medication 
was needed in 21/30 patients in the propofol group and in 8/30 
in the ketofol group. There were no cases of desaturation in 
the ketofol group, but in the propofol group 4/30 experienced 
desaturation and 6/30 had apnea. At both the three and five-
minute time intervals blood pressure and heart rate were 
significantly lower in the propofol group than in the ketofol 
group. In summary, the authors concluded that the addition of 
low dose ketamine to propofol reduced the risk of respiratory 
depression and the need for repeat medication administration.
In adults there is only one study comparing propofol 
monotherapy to ketofol. In this randomized double-blind 
study, 70 elderly patients receiving retrobulbar nerve blocks 
for cataract extraction were assigned to receive either 
propofol in small boluses or propofol in small boluses with 
the addition of ketamine (30 mg) in the first bolus.14 They 
found that patients in the ketofol group had a significantly 
shorter time until sedation (164 +/- 67 s) when compared to 
the propofol group (235 +/- 137 s). Also, two patients in the 
propofol group needed ventilatory assistance compared to 
zero patients in the ketofol group. This led these researchers 
to conclude that adding ketamine to propofol resulted in faster 
onset of sedation while decreasing respiratory compromise. 
It is important to note that the authors did not assess other 
important adverse events including emergence reactions and 
sympathomimetic effects, which are of special importance in 
elderly patients.
Ketofol versus Propofol-Fentanyl
Another popular drug combination for PSA consists of 
propofol and fentanyl, and there are two studies that compare 
ketofol to this combination. In a randomized double-blind 
study performed in 40 adult patients undergoing endometrial 
biopsy, the combination of propofol (1 mg/kg) plus fentanyl 
(1 ug/kg) was compared to the combination of propofol (1 
mg/kg) plus ketamine (0.5 mg/kg).15 Heart rate, systolic and 
diastolic blood pressure, respiratory rate, peripheral oxygen 
saturation, adverse events, time to recovery, and time to 
discharge were recorded. Although respiratory depression 
was five times more frequent in the ketofol group, neither 
this difference nor any other difference in vital signs was 
found to be statistically significant. Time to recovery was 
similar; however time to discharge was longer in the ketofol 
group secondary to the increased presence of adverse events 
including nausea, vertigo, and visual disturbances. In a post-
procedure phone follow-up interview conducted 24 hours 
after discharge 95% of patients in the propofol plus fentanyl 
group stated they were satisfied and would like the same 
combination in the future, versus only 60% of patients in the 
ketofol group. These authors concluded that although both 
regimens seem safe, ketofol had more adverse events leading 
to a longer time until discharge and had a lower overall patient 
satisfaction.
The second is a randomized double-blind study, in which 
90 total patients having a laryngeal mask airway (LMA) 
placed received propofol (2.5 mg/kg) with either ketamine 
(0.5 mg/kg), fentanyl (1 ug/kg), or placebo normal saline.16 
When measured vital signs and pre-determined time points 
and ease of LMA insertion, they found the ketofol group had 
a significantly higher systolic blood pressure than the other 
two groups and the incidence of prolonged apnea (>120 s) 
was higher in the fentanyl group (23.1%) than in either the 
ketofol group (6.3%) or the normal saline group (3.3%). They 
concluded that ketofol provided equivalent LMA insertion 
conditions while maximizing hemodynamics and minimizing 
apnea. Even though efficacy was assessed in this study, no 
attempt was made to qualify important adverse events such as 
emergence reactions.
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Table 1.  
Author/Journal Agents N Patients
Study 
Design
Setting Comments
Akin A. 
Pediatr Cardiol 
2005
Ketofol vs. 
Propofol
60 Children 1 
mo to 13 
years
Randomized 
double-blind
Cardiac 
catheterization
Improved MAP preservation without 
prolonging recovery or increasing adverse 
events in the ketofol group.
Akin A. 
Int J Pediatr 
Otorhinolaryngol 
2005
Ketofol vs. 
Propofol
60 Children 1 
mo to 13 
years
Non-
randomized
Auditory 
brainstem 
response testing
Decreased need for repeat dosing and 
decreased respiratory depression in the 
ketofol group.
Frey K.
Anesth Anag 1999
Ketofol vs. 
Propofol
70 Elderly Randomized 
double-blind
Cataract 
extraction
Faster onset of sedation and decreased 
respiratory depression in the ketofol group.  
No mention of emergence reactions or 
sympathomimetic effects.
Akin A.
J Clin Anesth 2005
Ketofol vs. 
Propofol + 
Fentanyl
40 Adults Randomized 
double-blind
Endometrial 
biopsy
Respiratory depression five times more 
frequent in the ketofol group but not 
statistically significant.  Adverse events 
including nausea, vertigo, and visual 
disturbances more common with ketofol 
resulting in longer time to discharge. Patient 
satisfaction lower with ketofol.
Goh PK.  
Anaesth Intensive 
Care 2005
Ketofol vs. 
Propofol + 
Fentanyl
90 Adults Randomized 
double-blind
LMA insertion Higher SBP less episodes of prolonged 
apnea (6.3%) with ketofol when compared 
with the Fentanyl group (23.1%)
Willman EV.
Ann Emerg Med 
2007
Ketofol 114 Adults Prospective 
descriptive
ED mainly 
orthopedic 
procedures
No hypotension.  One patient needed 
BVM ventilation.  Three patients had 
an emergence reaction.  No vomiting. 
Procedural success rate 96.5%.  Median time 
till recovery 15 minutes.  Median satisfaction 
score of 10.
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Ketofol in the Emergency Department
There is only one published prospective study using 
ketofol for PSA conducted in the ED setting. In this 
descriptive study 114 patients requiring PSA for mainly 
orthopedic procedures were given a 1:1 mixture of propofol 
(10 mg/ml) and ketamine (10 mg/ml) in 1 to 3 ml aliquots 
titrated at the discretion of the treating physician.17 They 
recorded dose administered, vital signs at pre-determined 
intervals, presence or absence of adverse events, procedural 
success, time until recovery, and physician, nurse and patient 
satisfaction. The mean dose of medication administered was 
0.75 mg/kg of ketamine and 0.75 mg/kg of propofol. No 
patient became hypotensive or had evidence of poor perfusion. 
Transient hypoxia occurred in 2.6% of patients (95% CI 0.6 to 
7.5%) and of these one (0.9%; 95% CI 0.02 to 4.8%) required 
bag valve mask ventilation. Three patients (2.6%; 95% CI 
0.6-7.5%) had an emergence reaction, one of whom received 
midazolam. No patient had vomiting or aspiration. Procedural 
success rate in this study without the use of adjunctive 
medications was 96.5%. Median time until recovery was 15 
minutes (range 5 to 45 minutes) and median physician, nurse, 
and patient satisfaction scores were 10 on a 1-to-10 scale.
discUssiOn
The combination of ketamine and propofol has been 
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but only recently has it begun to spread into other fields 
of medicine. Because ketofol is a relatively new idea for 
most practitioners, there is very little in scientific literature 
on its use in bolus form for PSA. The studies that have 
been conducted are small in size and thus lack the power 
to detect significant differences in all of their stated 
endpoints. Although most studies do attempt to evaluate 
safety as measured by respiratory and cardiovascular 
status, very few look at the frequency of other adverse 
events such as emergence reactions which, if present, may 
cause practitioners to veer away from ketofol and use 
another regimen that is found to be equally efficacious. 
Additionally, in the reviewed literature several different 
dosing regimens are used, making it hard to reconcile the 
results of the various studies. 
In the two pediatric studies discussed in this review 
the authors chose to compare ketofol to propofol 
monotherapy. It would have been more useful look for 
an efficacy difference between ketofol and ketamine 
monotherapy, which is used far more frequently than 
propofol monotherapy in children.12,13 Importantly, only 
one study was actually conducted in the ED setting with 
ED procedures using bolus dose ketofol.17 The authors 
found ketofol to be both safe and efficacious, but this study 
was purely descriptive and therefore cannot be used to 
conclude that the combination is better than either agent as 
monotherapy. It is unclear if the conclusions of the rest of 
the reviewed studies describing the use of ketofol in other 
clinical settings and types of procedures can be generalized 
to its use in the ED.
cOnclUsiOn
Although all but one of the published studies reviewed 
in this article conclude that the combination of ketamine 
and propofol in bolus form provides safer and more 
efficacious sedation, larger randomized, prospective studies 
conducted in the ED with sufficient power to use stability 
of vital signs and procedural success as endpoints are 
needed. From the literature reviewed one can conclude that 
ketofol appears to be safe and efficacious for use in the 
ED for PSA. However, as the reviewed studies are small, 
reporting of adverse events is often limited, and the only 
study conducted in the ED is not a randomized trial, the 
literature is not strong enough to definitively conclude that 
ketofol is better than either agent alone or than either agent 
used in combination with a different agent.
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